K. Gauvain

发表

Measurement of regional pulmonary blood flow with PET.

M. Welch, J. Markham, D. Schuster, 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition.

I. Harting, L. Hazrati, D. Eisenstat, 2020, JCO precision oncology.

Large Vessel Arteriopathy After Cranial Radiation Therapy in Pediatric Brain Tumor Survivors

C. Hess, D. Saloner, H. Fullerton, 2018, Journal of child neurology.

Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma.

M. Prados, L. Butterfield, J. Villanueva-Meyer, 2020, The Journal of clinical investigation.

Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)

C. Pratilas, K. Hutchinson, G. Meneses‐Lorente, 2022, Neuro-oncology.

Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma

T. MacDonald, M. Prados, D. Neuberg, 2018, Neuro-oncology.

Outcomes of Pediatric Low-grade Gliomas Treated With Radiation Therapy: A Single-institution Study

K. Gauvain, Sunil S. Raikar, Michael Elliot, 2014, Journal of pediatric hematology/oncology.

Phase I study of vemurafenib in children with recurrent or progressive BRAF V600E mutant brain tumors: Pacific Pediatric Consortium study (PNOC-002).

S. Mueller, S. Leary, A. Gajjar, 2020 .

Pilot Evaluation of a Palliative and End-of-Life Communication Intervention for Parents of Children With a Brain Tumor

C. Shih, V. Hendricks-Ferguson, J. Haase, 2017, Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology Nurses.

Evaluating pediatric brain tumor cellularity with diffusion-tensor imaging.

R C McKinstry, J J Neil, R. McKinstry, 2001, AJR. American journal of roentgenology.

Multi‐institutional analysis of treatment modalities in basal ganglia and thalamic germinoma

Michael Fisher, J. Finlay, Jeffrey C. Allen, 2021, Pediatric blood & cancer.

Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors.

K. Hutchinson, G. Meneses‐Lorente, A. Sabnis, 2019, Journal of Clinical Oncology.

PDCT-24. A PHASE I DOSE ESCALATION TRIAL OF THE MEK1/2 INHIBITOR MEK162 (BINIMETINIB) IN CHILDREN WITH LOW-GRADE GLIOMAS AND OTHER RAS-RAF PATHWAY-ACTIVATED TUMORS: INITIAL REPORT

Mariella G. Filbin, T. MacDonald, K. Ligon, 2017 .

Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma.

M. Prados, L. Butterfield, J. Villanueva-Meyer, 2022, The Journal of clinical investigation.

Resolution of precocious puberty following resection of fourth ventricular medulloblastoma: case report.

S. Elbabaa, D. Dempsher, K. Gauvain, 2015, Journal of neurosurgery. Pediatrics.

Updated entrectinib data in children and adolescents with recurrent or refractory solid tumors, including primary CNS tumors.

K. Hutchinson, A. Sabnis, A. Gajjar, 2020 .

Unusual high-grade features in pediatric diffuse leptomeningeal glioneuronal tumor: comparison with a typical low-grade example.

R. Schmidt, S. Dahiya, Katherine E Schwetye, 2017, Human pathology.

Grade II pilocytic astrocytoma in a 3‐month‐old patient with encephalocraniocutaneous lipomatosis (ECCL): Case report and literature review of low grade gliomas in ECCL

S. Braddock, Martin Reis, S. Elbabaa, 2015, American journal of medical genetics. Part A.

18F-FDOPA PET/MRI for monitoring early response to bevacizumab in children with recurrent brain tumors.

Ephraim E. Parent, M. Goyal, J. McConathy, 2018, Neuro-oncology practice.

Genetic and histopathological associations with outcome in pediatric pilocytic astrocytoma.

D. Limbrick, A. King, M. Chicoine, 2022, Journal of neurosurgery. Pediatrics.

Presence of cerebral microbleeds is associated with worse executive function in pediatric brain tumor survivors.

J. Lupo, R. Goldsby, H. Fullerton, 2016, Neuro-oncology.

RO-02CEREBRAL MICROBLEEDS ARE ASSOCIATED WITH WORSE EXECUTIVE FUNCTION IN PEDIATRIC BRAIN TUMOR SURVIVORS

J. Lupo, R. Goldsby, H. Fullerton, 2016 .

MRI Detection of Early Bone Metastases in B16 Mouse Melanoma Models

Sheng-Kwei Song, A. Hirbe, J. Garbow, 2005, Clinical & Experimental Metastasis.

Phase I study of vemurafenib in children with recurrent or progressive BRAFV600E mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002)

M. Prados, M. Aboian, A. Molinaro, 2020, Oncotarget.

Methodology for cost analysis of film-based and filmless portable chest systems

G. James Blaine, Gary S. Brink, G. J. Blaine, 1996, Medical Imaging.

Evaluation of Physician and Nurse Dyad Training Procedures to Deliver a Palliative and End-of-Life Communication Intervention to Parents of Children with a Brain Tumor

C. Shih, J. Baker, V. Hendricks-Ferguson, 2015, Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology Nurses.

Widely Metastatic Choroid Plexus Carcinoma Associated with Novel TP53 Somatic Mutation.

D. Limbrick, S. Dahiya, Rowland H. Han, 2018, World neurosurgery.

Rapidly Progressive Primary Leptomeningeal Atypical Teratoid/Rhabdoid Tumor

B. Durham, K. Gauvain, T. Geller, 2012, Journal of child neurology.

LGG-44. A PHASE I DOSE ESCALATION TRIAL OF THE MEK1/2 INHIBITOR MEK162 (BINIMETINIB) IN CHILDREN WITH LOW-GRADE GLIOMAS AND OTHER RAS/RAF PATHWAY-ACTIVATED TUMORS

K. Ligon, R. Sposto, M. Borchert, 2018, Neuro-Oncology.

LGG-55. OUTCOME OF BRAF V600E PEDIATRIC GLIOMAS TREATED WITH TARGETED BRAF INHIBITION

I. Harting, L. Hazrati, D. Eisenstat, 2020, Neuro-Oncology.

Pilot Evaluation of a Palliative and End-of-Life Communication Intervention for Parents of Children With a Brain Tumor

C. Shih, V. Hendricks-Ferguson, J. Haase, 2017, Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology Nurses.

Phase 1 study of entrectinib (RXDX-101), a TRK, ROS1, and ALK inhibitor, in children, adolescents, and young adults with recurrent or refractory solid tumors.

G. Brodeur, A. Sabnis, P. Multani, 2018 .